IL-1 dysregulation and potential use of IL-1 blockade is currently under consideration in many other diseases ranging from atherosclerosis, acute myocardial infarction, heart failure, myocarditis and dilated cardiomyopathy to type 2 diabetes mellitus and many other conditions. This evidence concerns the gene IL1A and heart failure.